These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 17482743)

  • 1. Formation and persistence of DNA adducts of anticancer drug ellipticine in rats.
    Stiborová M; Rupertová M; Aimová D; Ryslavá H; Frei E
    Toxicology; 2007 Jul; 236(1-2):50-60. PubMed ID: 17482743
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The anticancer drug ellipticine is a potent inducer of rat cytochromes P450 1A1 and 1A2, thereby modulating its own metabolism.
    Aimová D; Svobodová L; Kotrbová V; Mrázová B; Hodek P; Hudecek J; Václavíková R; Frei E; Stiborová M
    Drug Metab Dispos; 2007 Oct; 35(10):1926-34. PubMed ID: 17656468
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rat microsomes activating the anticancer drug ellipticine to species covalently binding to deoxyguanosine in DNA are a suitable model mimicking ellipticine bioactivation in humans.
    Stiborová M; Stiborová-Rupertová M; Borek-Dohalská L; Wiessler M; Frei E
    Chem Res Toxicol; 2003 Jan; 16(1):38-47. PubMed ID: 12693029
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of hepatic cytochromes P450 in bioactivation of the anticancer drug ellipticine: studies with the hepatic NADPH:cytochrome P450 reductase null mouse.
    Stiborová M; Arlt VM; Henderson CJ; Wolf CR; Kotrbová V; Moserová M; Hudecek J; Phillips DH; Frei E
    Toxicol Appl Pharmacol; 2008 Feb; 226(3):318-27. PubMed ID: 17976674
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DNA adduct formation by the anticancer drug ellipticine in rats determined by 32P postlabeling.
    Stiborová M; Breuer A; Aimová D; Stiborová-Rupertová M; Wiessler M; Frei E
    Int J Cancer; 2003 Dec; 107(6):885-90. PubMed ID: 14601046
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The mechanism of cytotoxicity and DNA adduct formation by the anticancer drug ellipticine in human neuroblastoma cells.
    Poljaková J; Eckschlager T; Hrabeta J; Hrebacková J; Smutný S; Frei E; Martínek V; Kizek R; Stiborová M
    Biochem Pharmacol; 2009 May; 77(9):1466-79. PubMed ID: 19426684
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of cytochromes P450 and peroxidases in metabolism of the anticancer drug ellipticine: additional evidence of their contribution to ellipticine activation in rat liver, lung and kidney.
    Stiborova M; Moserova M; Mrazova B; Kotrbova V; Frei E
    Neuro Endocrinol Lett; 2010; 31 Suppl 2():26-35. PubMed ID: 21187821
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The anticancer drug ellipticine forms covalent DNA adducts, mediated by human cytochromes P450, through metabolism to 13-hydroxyellipticine and ellipticine N2-oxide.
    Stiborová M; Sejbal J; Borek-Dohalská L; Aimová D; Poljaková J; Forsterová K; Rupertová M; Wiesner J; Hudecek J; Wiessler M; Frei E
    Cancer Res; 2004 Nov; 64(22):8374-80. PubMed ID: 15548707
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oxidation pattern of the anticancer drug ellipticine by hepatic microsomes - similarity between human and rat systems.
    Stiborová M; Borek-Dohalská L; Aimová D; Kotrbová V; Kukacková K; Janouchová K; Rupertová M; Ryslavá H; Hudecek J; Frei E
    Gen Physiol Biophys; 2006 Sep; 25(3):245-61. PubMed ID: 17197724
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mammalian peroxidases activate anticancer drug ellipticine to intermediates forming deoxyguanosine adducts in DNA identical to those found in vivo and generated from 12-hydroxyellipticine and 13-hydroxyellipticine.
    Stiborová M; Poljaková J; Ryslavá H; Dracínský M; Eckschlager T; Frei E
    Int J Cancer; 2007 Jan; 120(2):243-51. PubMed ID: 17066455
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Formation, persistence, and identification of DNA adducts formed by the carcinogenic environmental pollutant o-anisidine in rats.
    Naiman K; Dracínský M; Hodek P; Martínková M; Schmeiser HH; Frei E; Stiborová M
    Toxicol Sci; 2012 Jun; 127(2):348-59. PubMed ID: 22403159
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytotoxicity of and DNA adduct formation by ellipticine in human U87MG glioblastoma cancer cells.
    Martinkova E; Dontenwill M; Frei E; Stiborova M
    Neuro Endocrinol Lett; 2009; 30 Suppl 1():60-6. PubMed ID: 20027146
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DNA adduct formation by the anticancer drug ellipticine in human leukemia HL-60 and CCRF-CEM cells.
    Poljaková J; Frei E; Gomez JE; Aimová D; Eckschlager T; Hrabeta J; Stiborová M
    Cancer Lett; 2007 Jul; 252(2):270-9. PubMed ID: 17306925
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytochromes P450 reconstituted with NADPH: P450 reductase mimic the activating and detoxicating metabolism of the anticancer drug ellipticine in microsomes.
    Kotrbová V; Aimová D; Brezinová A; Janouchová K; Poljaková J; Frei E; Stiborová M
    Neuro Endocrinol Lett; 2006 Dec; 27 Suppl 2():18-22. PubMed ID: 17159771
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anticancer agent ellipticine combined with histone deacetylase inhibitors, valproic acid and trichostatin A, is an effective DNA damage strategy in human neuroblastoma.
    Poljakova J; Hrebackova J; Dvorakova M; Moserova M; Eckschlager T; Hrabeta J; Göttlicherova M; Kopejtkova B; Frei E; Kizek R; Stiborova M
    Neuro Endocrinol Lett; 2011; 32 Suppl 1():101-16. PubMed ID: 22167207
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of covalent ellipticine- and doxorubicin-derived adducts in DNA of neuroblastoma cells by the ³²P-postlabeling technique.
    Stiborova M; Poljakova J; Eckschlager T; Kizek R; Frei E
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2012 Jun; 156(2):115-21. PubMed ID: 22837132
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oxidation of an antitumor drug ellipticine by peroxidases.
    Poljaková J; Forsterová K; Sulc M; Frei E; Stiborová M
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2005 Dec; 149(2):449-53. PubMed ID: 16601808
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Persistence of platinum-ammine-DNA adducts in gonads and kidneys of rats and multiple tissues from cancer patients.
    Poirier MC; Reed E; Litterst CL; Katz D; Gupta-Burt S
    Cancer Res; 1992 Jan; 52(1):149-53. PubMed ID: 1727376
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ochratoxin a causes DNA damage and cytogenetic effects but no DNA adducts in rats.
    Mally A; Pepe G; Ravoori S; Fiore M; Gupta RC; Dekant W; Mosesso P
    Chem Res Toxicol; 2005 Aug; 18(8):1253-61. PubMed ID: 16097798
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The formation and persistence of carboplatin-DNA adducts in rats.
    Blommaert FA; Michael C; van Dijk-Knijnenburg HC; Schornagel JH; den Engelse L; Fichtinger-Schepman AM
    Cancer Chemother Pharmacol; 1996; 38(3):273-80. PubMed ID: 8646803
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.